BioWorld

Jan. 11, 2002

Corixa’s Bexxar ODAC Hearing Delayed While FDA Sorts Data

Despite reassurances from Corixa Corp. that there s nothing wrong with its lead drug candidate, Bexxar, the Seattle company s stock tumbled Thursday on news that the FDA has delayed an application hearing for the product. Read More

Access Oncology To Pay Up To $33M For Doxorubicin Analogues

Old Order Changeth; Genomics Yields Place To New Proteomics For Deciphering Gene Functions

GenVec To Collaborate With NIH On AIDS Vaccine Development

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 1, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...

Handshake, businessmen holding dollar sign, lightbulb

Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal

BioWorld

A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...